T 0814/12 (Target in PI3-kinase pathway/SILENCE THERAPEUTICS) of 20.10.2016
- European Case Law Identifier
- ECLI:EP:BA:2016:T081412.20161020
- Date of decision
- 20 October 2016
- Case number
- T 0814/12
- Petition for review of
- -
- Application number
- 03790894.4
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Use of protein kinase N beta
- Applicant name
- Silence Therapeutics GmbH
- Opponent name
- Alnylam Pharmaceuticals Inc.
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 15(3)
- Keywords
- -
- Catchword
- -
- Cited cases
- T 0241/95
- Citing cases
- T 0589/22
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the following claims and a description to be adapted thereto:
Claims 1 to 20 filed as main request during the oral proceedings of 20 October 2016.